{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T16:31:05Z","timestamp":1749486665272},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2020,3,1]]},"DOI":"10.1001\/jamaophthalmol.2019.5831","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T11:31:02Z","timestamp":1580383862000},"page":"276","source":"Crossref","is-referenced-by-count":6,"title":["Characteristics of Eyes With Good Visual Acuity at 5 Years After Initiation of Treatment for Age-Related Macular Degeneration but Not Receiving Treatment From Years 3 to 5"],"prefix":"10.1001","volume":"138","author":[{"given":"Drew","family":"Scoles","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gui-shuang","family":"Ying","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiying","family":"Hua","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan E.","family":"Grunwald","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ebenezer","family":"Daniel","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn J.","family":"Jaffe","sequence":"additional","affiliation":[{"name":"Duke Eye Center, Duke University, Durham, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia A.","family":"Toth","sequence":"additional","affiliation":[{"name":"Duke Eye Center, Duke University, Durham, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel F.","family":"Martin","sequence":"additional","affiliation":[{"name":"Cole Eye Institute, The Cleveland Clinic, Cleveland, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen G.","family":"Maguire","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Comparison of AMD Treatments Trials Research Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"7","key":"eoi190097r1","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"issue":"20","key":"eoi190097r2","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration.","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"eoi190097r3","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ophtha.2014.07.041","article-title":"Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol.","volume":"122","author":"Berg","year":"2015","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi190097r4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","article-title":"Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.","volume":"116","author":"Brown","year":"2009","journal-title":"Ophthalmology"},{"issue":"9900","key":"eoi190097r5","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial.","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"issue":"11","key":"eoi190097r6","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1016\/j.ophtha.2013.06.020","article-title":"Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial.","volume":"120","author":"Kodjikian","year":"2013","journal-title":"Ophthalmology"},{"issue":"12","key":"eoi190097r7","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"issue":"8","key":"eoi190097r8","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-year outcomes with anti\u2013vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the Comparison of Age-Related Macular Degeneration Treatments Trials.","volume":"123","author":"Maguire","year":"2016","journal-title":"Ophthalmology"},{"issue":"6","key":"eoi190097r9","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.oret.2017.10.003","article-title":"Baseline predictors for five-year visual acuity outcomes in the comparison of AMD treatment trials.","volume":"2","author":"Ying","year":"2018","journal-title":"Ophthalmol Retina"},{"issue":"12","key":"eoi190097r10","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1136\/bjophthalmol-2014-305186","article-title":"Intraretinal cysts are the most relevant prognostic biomarker in neovascular age-related macular degeneration independent of the therapeutic strategy.","volume":"98","author":"Ritter","year":"2014","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"eoi190097r11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ophtha.2018.08.035","article-title":"Macular morphology and visual acuity in year five of the Comparison of Age-Related Macular Degeneration Treatments Trials.","volume":"126","author":"Jaffe","year":"2019","journal-title":"Ophthalmology"},{"issue":"9","key":"eoi190097r12","doi-asserted-by":"publisher","first-page":"5040","DOI":"10.1167\/iovs.15-16494","article-title":"Baseline predictors for good versus poor visual outcomes in the treatment of neovascular age-related macular degeneration with intravitreal anti-VEGF therapy.","volume":"56","author":"Chae","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"eoi190097r13","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ophtha.2012.07.042","article-title":"Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration.","volume":"120","author":"Ying","year":"2013","journal-title":"Ophthalmology"},{"issue":"7","key":"eoi190097r14","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1097\/IAE.0000000000000483","article-title":"Identification of fluid on optical coherence tomography by treating ophthalmologists versus a reading center in the Comparison of Age-Related Macular Degeneration Treatments Trials.","volume":"35","author":"Toth","year":"2015","journal-title":"Retina"},{"issue":"1","key":"eoi190097r15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","article-title":"Risk of geographic atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials.","volume":"121","author":"Grunwald","year":"2014","journal-title":"Ophthalmology"},{"issue":"8","key":"eoi190097r16","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/j.ophtha.2012.02.013","article-title":"Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials.","volume":"119","author":"Grunwald","year":"2012","journal-title":"Ophthalmology"},{"issue":"3","key":"eoi190097r17","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ophtha.2013.10.019","article-title":"Risk of scar in the Comparison of Age-Related Macular Degeneration Treatments Trials.","volume":"121","author":"Daniel","year":"2014","journal-title":"Ophthalmology"},{"issue":"7","key":"eoi190097r18","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.ophtha.2018.01.004","article-title":"Development and course of scars in the Comparison of Age-Related Macular Degeneration Treatments Trials.","volume":"125","author":"Daniel","year":"2018","journal-title":"Ophthalmology"},{"issue":"8","key":"eoi190097r19","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.oret.2019.05.013","article-title":"Outcomes of suspending VEGF inhibitors for neovascular age-related macular degeneration when lesions have been inactive for 3 months.","volume":"3","author":"Nguyen","year":"2019","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"eoi190097r20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/IAE.0000000000001923","article-title":"Exit strategy in a treat-and-extend regimen for exudative age-related macular degeneration.","volume":"39","author":"Arendt","year":"2019","journal-title":"Retina"},{"issue":"5","key":"eoi190097r21","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1097\/IAE.0000000000001282","article-title":"Long-term outcomes and incidence of recurrence of neovascularization in treated exudative age-related macular degeneration.","volume":"37","author":"Haddad","year":"2017","journal-title":"Retina"},{"issue":"3","key":"eoi190097r22","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/IAE.0000000000001572","article-title":"Long-term remission of neovascular age-related macular degeneration with as-needed anti\u2013vascular endothelial growth factor therapy.","volume":"38","author":"Muftuoglu","year":"2018","journal-title":"Retina"},{"issue":"3","key":"eoi190097r23","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.ophtha.2015.10.034","article-title":"Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).","volume":"123","author":"Daniel","year":"2016","journal-title":"Ophthalmology"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2759804\/jamaophthalmology_scoles_2020_oi_190097.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T11:00:55Z","timestamp":1584010855000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2759804"}},"subtitle":["Post Hoc Analysis of the CATT Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2020,3,1]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2019.5831","relation":{},"ISSN":["2168-6165"],"issn-type":[{"type":"print","value":"2168-6165"}],"subject":[],"published":{"date-parts":[[2020,3,1]]}}}